SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zebra 365 who wrote (2308)11/10/1997 10:42:00 AM
From: Cacaito  Read Replies (1) of 23519
 
Zebra, New numbers are out in that Spain conference. Now they are down from the much hyped 80s% in Padma-Nathan interviews, to 59% of organic ED from Pfizer's recent pr, and now the Medical Tribune range of 40% to 59% in severe organic ED, only 59 patients and no age, neither disease distribution, neither a definition of "severe organic ED".

It does look that we will have to wait more for the full data.

In the same conference ther was an annoucement of Padma-Nathan and Irwin Goldstein plan US type III trial of Invicorp from Senetek.

Now Pfizer numbers are getting closer to Zona's 37% to 40%.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News